Editorial: Don't forget the orphans

European Journal of Health Law

Volumn 22, Issue 2, 2015, Pages 107-111

  Grewal, Jasjote ^a   Hoppe, Nils ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG MANUFACTURE; EUROPE; HUMAN; LEGISLATION AND JURISPRUDENCE; NEEDS ASSESSMENT; RARE DISEASE;

EUROPE; HUMANS; NEEDS ASSESSMENT; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84926304461     PISSN: 09290273     EISSN: 15718093     Source Type: Journal    
DOI: 10.1163/15718093-12341351     Document Type: Review

References (12)

1. L.A. Barrera and G.C. Galindo, 'Ethical aspects on rare diseases', Adv Exp Med Biol 686 (2010) 493-511.
2. J.E. Davies, S. Neidle and D.G. Taylor, 'Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?', Br J Cancer 106(1) (2012) 14-17.
3. A. Kole and F. Faurisson, 'Rare diseases social epidemiology: analysis of inequalities', Adv Exp Med Biol 686 (2010) 223-250.
4. H.I. Hyry, J.C. Roos, J. Manuel and T.M. Cox, 'The legal imperative for treating rare disorders', Orphanet J Rare Dis 8 (2013) 135.
5. G. Michaux, 'EU orphan regulation - ten years of application', Food Drug Law J 65(4) (2010) 639-669.
6. M. Wästfelt, B. Fadeel and J.I. Henter, 'A journey of hope: lessons learned from studies on rare diseases and orphan drugs', Journal of Internal Medicine 260(1) (2006) 1-10.
7. G.S. Ginsburg and J.J. McCarthy, 'Personalized medicine: revolutionizing drug discovery and patient care', Trends in Biotechnology 19(12) (2001) 491-496.
8. M. Herder, 'When everyone is an orphan: Against adopting a US-styled orphan drug policy in Canada', Accountability in Research-Policies and Quality Assurance 20(4) (2013) 227-269.
9. A. Rinaldi, 'Adopting an orphan', EMBO Rep 6(6) (2005) 507-510.
10. A. Montserrat Moliner and J. Waligora, 'The European union policy in the field of rare diseases', Public Health Genomics 16(6) (2013) 268-277.
11. H.E. Heemstra, S. van Weely, H.A. Buller, H.G. Leufkens and R.L. de Vrueh, 'Translation of rare disease research into orphan drug development: disease matters', Drug Discov Today 14(23-24) (2009) 1166-1173.
12. A. Paturel, 'Too Rare for Research? People with rare diseases often experience significant delays in diagnosis and access to few, if any, treatment options', Neurology Now 8(2) (2012) 29-33.